Shahgordi Sanaz, Oroojalian Fatemeh, Hashemi Ezzat, Hashemi Maryam
Immunology Department, Faculty of Medicine, Golestan University of Medical Science, Gorgan, Iran.
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Iran J Basic Med Sci. 2022 Feb;25(2):134-147. doi: 10.22038/IJBMS.2022.59718.13245.
Immunotherapy is a novel preference for the treatment of various complex diseases. Considering the application of varying agents for suppression or activation of the immune system, immunogene therapy was confirmed to stand as a proper alternative for other immunotherapeutic strategies due to its capability in targeting cells with more specificity that leads to controlling the expression of therapeutic genes. This method facilitates the local and single-dose application of most gene therapies that result in the usage of high therapeutic doses with a low risk of systemic side effects while being cost-efficient in long-term administrations. However, the existing barriers between the administration site and cell nucleus limited the clinical uses of genetic materials. These challenges can be overcome through the promising method of exerting non-carriers with high stability, low toxicity/immunogenicity, and simple modifications. In this study, we attempted to review the potential of nanoparticle application throughout the immunogene therapy of different diseases including cancer, microbial diseases, allergies, inflammatory bowel disease, rheumatoid arthritis, and respiratory infections. We included the outline of some challenges and opportunities in regards to the delivery of genetic materials that are based on nano-systems through immunotherapy of these disorders. Next to the promising future of these vectors, more detailed analyses are required to overcome the current limitations in clinical approaches.
免疫疗法是治疗各种复杂疾病的一种新选择。考虑到用于抑制或激活免疫系统的各种药物的应用,免疫基因疗法因其能够更特异性地靶向细胞从而控制治疗基因的表达,被确认为是其他免疫治疗策略的合适替代方法。这种方法有助于大多数基因疗法的局部和单剂量应用,从而在使用高治疗剂量时全身副作用风险较低,且长期给药具有成本效益。然而,给药部位与细胞核之间存在的现有障碍限制了遗传物质的临床应用。通过采用具有高稳定性、低毒性/免疫原性且易于修饰的非载体这一有前景的方法,可以克服这些挑战。在本研究中,我们试图综述纳米颗粒在包括癌症、微生物疾病、过敏、炎症性肠病、类风湿性关节炎和呼吸道感染在内的不同疾病的免疫基因治疗中的应用潜力。我们概述了基于纳米系统通过这些疾病的免疫疗法递送遗传物质方面的一些挑战和机遇。除了这些载体的光明前景之外,还需要更详细的分析来克服当前临床方法中的局限性。